Tiziana Fernández-Mincone

Tiziana Fernández-Mincone

Auto-generated profile, based on publicly available information

Tiziana Fernández-Mincone

Affiliation Departamento Ciencias de la Salud, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 February 2022 in PLOS ONE
Verified
Journal Article
Open access
PDF file
TFTiziana Fernández
Tiziana Fernández
MVMacarena Viñuela
Macarena Viñuela
CVCatalina Vidal
Catalina Vidal
FBFrancisco Barrera
Francisco Barrera
Background: Non-alcoholic fatty liver disease is a liver condition that is increasing worldwide and expected to become the number one cause of cirrhosis and hepatocellular carcinoma in the next 5 years. Currently there are no successful or approved pharmacological treatments. Weight loss is the first-line therapy as a 7 to 10% reduction improves steatosis, inflammation, hepatocyte ballooning, and fibrosis. To achieve this, lifestyle interventions including daily exercise and diet must be encouraged. We aimed to assess the effects of diet, exercise, or a combination of both compared to conventional treatment in patients with non-alcoholic fatty liver disease. Methods and finding: A literature search was performed in CENTRAL, EMBASE, and PubMed. Randomized controlled trials comparing lifestyle changes with conventional treatment were included, without date restriction. Two authors searched studies according to eligibility criteria, extracted data, and assessed study quality. Subgroup analysis was made by type of intervention, duration of intervention and supervision. We calculated mean differences between the intervention and the control group with their corresponding 95% confidence intervals. Quality of the evidence was assessed using the Cochrane Risk of bias tool. This study is registered in PROSPERO, number CRD42020184241, and checked with the PRISMA checklist. 30 RCTs met the inclusion criteria. Compared to conventional treatment, combined exercise with diet seems to elicit greater reductions in ALT (MD: -13.27 CI 95% -21.39, -5.16), AST (MD: -7.02 CI 95% -11.26, -2.78) and HOMA-IR (MD: -2.07 CI 95% -2.61, -1.46) than diet (ALT MD: -4.48 CI 95% -1.01, -0.21; HOMA-IR MD: -0.61 CI 95% -1.01, -0.21) and exercise (ALT and AST non-significant; HOMA-IR MD = -0.46 CI 95% -0.8, -0.12) alone. Additionally, exercise improved quality of life, cardiorespiratory fitness, and weight (MD: -2.64 CI 95% -5.18, -0.09). Conclusion: Lifestyle changes are effective in the treatment of NAFLD. Diet and exercise combined are superior to these interventions alone in improving liver enzymes and HOMA-IR.

11 September 2020 in Expert Review of Gastroenterology & Hepatology
Verified
Journal Article
Closed access
TFTiziana Fernández-Mincone
Tiziana Fernández-Mincone
Felipe Contreras–BriceñoFelipe Contreras–Briceño
Felipe Contreras–Briceño
MEMaximiliano Espinosa
Maximiliano Espinosa
PGPatricio García-Valdés
Patricio García-Valdés
ALAntonio López-Fuenzalida
Antonio López-Fuenzalida
FBFrancisco Barrera
Francisco Barrera
Non-alcoholic fatty liver disease (NAFLD) is currently one of the most common liver diseases worldwide. Recent data suggest that loss of skeletal muscle mass and function (i.e. sarcopenia) is highl...

23 June 2020 in medRxiv
Verified
Preprint
Open access
PDF file
TFTiziana Fernández-Mincone
Tiziana Fernández-Mincone
MMMacarena Viñuela Morales
Macarena Viñuela Morales
MAMarco Arrese
Marco Arrese
JAJuan Pablo Arab
Juan Pablo Arab
DCDaniel Cabrera
Daniel Cabrera
FBFrancisco Barrera
Francisco Barrera
Non-alcoholic fatty liver disease (NAFLD) is a worldwide raising liver condition and it is expected to become the first cause of progression to cirrhosis and hepatocellular carcinoma in the next 5 years (Araújo 2018). At present, there are no pharmacological treatments approved. Weight loss is the first-line treatment (European Association for the Study of the Liver 2016) (Chalasani 2012) showing that 7 to 10% weight loss improves steatosis, inflammation, hepatocyte ballooning and, in NASH patients, has an impact in fibrosis too (Romero-Gómez 2017). However, the reduction and maintenance of weight loss is often complex. To achieve this goal, it is recommended doing lifestyle changes including exercise and diet on daily living (Hannah 2016). However, it has been difficult to establish any conclusions regarding the best type of diet or exercise protocol to maximize improvements and to maintain its effects through time. Because of this, the objective of this review is assessing the efficacy and safety of diet, exercise, or a combination of these in patients with NAFLD.